Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P603 Persistence of vedolizumab maintenance therapy: Findings from a Belgian registry

ECCO'20 Vienna

Year: 2020
Authors:

E. Louis1, V. Muls2, P. Bossuyt3, A. Colard4, A. Nakad5, D. Baert6, F. Mana7, P. Caenepeel8, S. Vanden Branden9, S. Vermeire10, F. D’Heygere11, B. Strubbe12, A. Cremer13, J.C. Coche14, V. Setakhr15, F. Baert16, A. Vijverman17, J.L. Coenegrachts18, F. Flamme19, A. Hantson20, K. Wijnen20, E. Piters20, P. Dolin21

1Department of Gastroenterology, University Hospital CHU of Liège, Liege, Belgium, 2Department of Gastroenterology, Saint Pierre University Hospital, Brussels, Belgium, 3Department of Gastroenterology, Imelda ziekenhuis, Bonheiden, Belgium, 4Department of Gastroenterology, Hospital CHC, Liège, Belgium, 5Department of Gastroenterology, CHwapi Notre Dame, Tournai, Belgium, 6Department of Gastroenterology, Maria Middelares Medical Centre, Ghent, Belgium, 7Department of Gastroenterology, UZ Brussel- Vrije Universiteit Brussel, Brussels, Belgium, 8Department of Gastroenterology, Ziekenhuis Oost Limburg, Genk, Belgium, 9Department of Gastroenterology, Onze Lieve Vrouwziekenhuis, Aalst, Belgium, 10Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium, 11Department of Gastroenterology, AZ Groeninge Hospital, Kortrijk, Belgium, 12Department of Gastroenterology, AZ St Lucas,Gent, Belgium, 13Department of Gastroenterology, Hopital Universitaire Erasme, Brussels, Belgium, 14Department of Gastroenterology, Clinique St Pierre, Ottignies, Belgium, 15Department of Gastroenterology, CHU UCL Namur site Sainte Elisabeth, Brussels, Belgium, 16Department of Gastroenterology, AZ Delta, Roeselare, Belgium, 17Department of Gastroenterology, Hospital CHR de la Citadelle, Liège, Belgium, 18Department of Gastroenterology, Jessa Ziekenhuis- Hasselt, Hasselt, Belgium, 19Department of Gastroenterology, CHU Ambroise Paré, Mons, Belgium, 20Department of Medical Affairs, Takeda Pharmaceuticals, Brussels, Belgium, 21Department of Epidemiology, Takeda Pharmaceuticals, London, UK

P604 Can we reduce intravenous monoclonal antibody observation times without compromising patient safety? A single centre retrospective observational study

ECCO'20 Vienna

Year: 2020
Authors:

F. REES1, A. Packham1, C. Blake1, E. Hills1, G. Scutt2, A. St Clair-Jones1

1Brighton and Sussex University Hospitals, IBD Team- Gastroenterology, Brighton, UK, 2University of Brighton, Pharmacy, Brighton, UK

P605 Eight-year efficacy and safety of azathioprine treatment in the maintenance of steroid-free remission in inflammatory bowel disease patients

ECCO'20 Vienna

Year: 2020
Authors:

C. Cassieri1, R. Pica2, E.V. Avallone1, G. Brandimarte3, M. Zippi2, P. Crispino1, D. De Nitto2, P.G. Lecca3, P. Vernia1, R. Pica2, E.S. Corazziari1

1University of Rome Sapienza, Department of Gastroenterology, Department of Internal Medicine and Medical Specialties, Rome, Italy, 2Sandro Pertini Hospital, Unit of Gastroenterology and Digestive Endoscopy, Rome, Italy, 3‘Cristo Re’ Hospital, Internal Medicine, Internal Medicine, Italy

P606 Exclusive enteral nutrition with a polymeric diet is efficacious in inducing remission in adults with active Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

P. Kakkadasam Ramaswamy1, R. Mutsekwa2, X. Lan2, Y. Chen2, R. Angus2, H. Moattar1, J. Edwards1, D. Shukla1

1Department of Gastroenterology, Gold Coast University Hospital, Southport, Australia, 2Department of Nutrition and Food Services, Gold Coast University Hospital, Southport, Australia

P607 Cost-effectiveness of vedolizumab IV vs. adalimumab SC for moderately to severely active ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

R. Schultz1, I. Diakite2, J. Carter2, S. Snedecor2, R. Turpin3

1Takeda Pharmaceuticals U.S.A.- Inc., Gastroenterology, Deerfield, USA, 2Pharmerit International, Gastroenterology, Bethesda, USA, 3Takeda Pharmaceuticals U.S.A.- Inc.., Gastroenterology, Lake Zurich, USA

P608 Endoscopic treatment of enterocutaneous fistulas in Crohn’s disease patient

ECCO'20 Vienna

Year: 2020
Authors:

C. Yzet, J.P. Le Mouel, S. Hakim, F. Brazier, M. Fumery

Amiens university hospital, Gastroenterology, Amiens, France

P609 An IBD dermatology multidisciplinary clinic: A single tertiary centre experience

ECCO'20 Vienna

Year: 2020
Authors:

N. Levy1, H. Matz2, N. Maharshak3, A. Waizbard4

1Tel Aviv Sourasky medical center, Internal medicine I, Tel Aviv, Israel, 2Tel Aviv Sourasky medical center, Department of Dermatology, Tel Aviv, Israel, 3Tel Aviv Sourasky medical center, Department of Gastroenterology and Liver diseases, Tel Aviv, Israel, 4Sanz Medical Center Laniado Hospital, Department of Gastroenterology, Netanya, Israel

P610 Optimising biological therapy in inflammatory bowel disease patients: the role of a virtual biological clinic

ECCO'20 Vienna

Year: 2020
Authors:

J. REES, C. Maher, J. Jones, J. Slater, B. Bates, D. Rattehalli, S. De Silva

Russells Hall Hospital, Gastroenterology, Dudley, UK

P611 Provision of care for pregnant women with IBD in the UK - the current landscape

ECCO'20 Vienna

Year: 2020
Authors:

E. Moore1, S. Wolloff1, T. Glanville2, C.P. Selinger1

1St James’ University Hospital, Gastroenterology, Leeds, UK, 2St James’ University Hospital, Obstetrics, Leeds, UK

P612 Dietary practices and beliefs of British South Asians with inflammatory bowel disease: A prospective UK study

ECCO'20 Vienna

Year: 2020
Authors:

B. Crooks1, J. McLaughlin2, J.K. Limdi1

1Department of Gastroenterology, Northern Care Alliance, Manchester, UK, 2Division of Diabetes- Endocrinology and Gastroenterology, University of Manchester, Manchester, UK

P613 Use of adalimumab biosimilar ABP 501 in Crohn’s disease: A real-life experience

ECCO'20 Vienna

Year: 2020
Authors:

D.G. Ribaldone1, M. Vernero2, R. Pellicano3, M. Morino1, G.M. Saracco4, M. Astegiano3

1Department of Surgical Sciences, University of Turin, Turin, Italy, 2First Department of Internal Medicine, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy, 3Unit of Gastroenterology, Molinette Hospital, Turin, Italy, 4Department of Medical Sciences, University of Turin, Turin, Italy

P614 Micro-fragmented autologous adipose tissue injection for fistula-in-ano (MAATIFA) in patients with Crohn’s disease: A prospective observational study

ECCO'20 Vienna

Year: 2020
Authors:

A. Sturiale1, B. Fabiani1, D. Cafaro1, C. Menconi1, F. Celedon Porzio1, M. Franceschi2, G. Naldini1

1Proctological and Pelvic Floor Clinical Centre, University Hospital of Pisa, Pisa, Italy, 2Inflammatory Bowel Disease Surgical Unit, University Hospital of Pisa, Pisa, Italy

P615 Safety of vedolizumab in the treatment of IBD in a single tertiary centre

ECCO'20 Vienna

Year: 2020
Authors:

G. Peruzzi, L. Calandrini, H. Privitera Hrustemovic, M. Salice, A. Decorato, A. Carbone, F. Rizzello, A. Belluzzi, E. Scaioli, C. Calabrese, P. Gionchetti

Policlinico Sant’Orsola-Malpighi, Malattie Infiammatorie Croniche Intestinali Prof. Gionchetti, Bologna, Italy

P616 IBD reference and biosimilar adalimumab CroSS over study (iBaSS): design considerations and methodology

ECCO'20 Vienna

Year: 2020
Authors:

D. Young1, U. Freudensprung2, C. Harris1, R. Harris1, J. Harvey3, J. Addison4, S. Latter5, F. Cummings1

1University Hospital Southampton NHS Foundation Trust, Department of Gastroenterology, Southampton, UK, 2Biogen International GmbH, n/a, Baar, Switzerland, 3University of Stellenbosch, Department of Statistics and Actuarial Science, Stellenbosch, South Africa, 4Biogen Idec, n/a, Maidenhead, UK, 5University of Southampton, School of Health Sciences, Southampton, UK

P617 Mesenchymal stromal cells of bone marrow reduce the risk of postoperative recurrence of Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

O. Knyazev, A.V. Kagramanova, A. Lishchinskaya, A. Parfenov

Department of IBD, Moscow Scientific Center named after A. S. Loginov, Moscow, Russian Federation

P618 Post-operative Crohn’s disease patients undergoing colonoscopy require significantly more analgesia and sedation compared with a non-IBD population

ECCO'20 Vienna

Year: 2020
Authors:

C. Rowan1, M. Janjua1, C. Foley1, J. Burke2, K. Boland1, A. O’Toole1

1Beaumont Hospital, Department of Gastroenterology, Dublin, Ireland, 2Beaumont Hospital, Department of Colorectal Surgery, Dublin, Ireland

P619 Efficacy of zinc acetate hydrate administration for zinc deficiency in patients with inflammatory bowel disease: a multi-centre retrospective study

ECCO'20 Vienna

Year: 2020
Authors:

K. Sakurai1, T. Katsurada1, S. Otagiri1, K. Yamanashi1, K. Nagashima1, R. Onishi1, H. Nishimura2, T. Ito2, S. Furukawa2, A. Maemoto2, N. Sakamoto1

1Hokkaido University Hospital, Department of Gastroenterology, Sapporo City- Hokkaido, Japan, 2Sapporo Higashi Tokushukai Hospital, Inflammatory Bowel Disease Center, Sapporo City- Hokkaido, Japan

P620 Maintenance of clinical remission with SB5 biosimilar after switch from adalimumab originator: Real-life experience of a tertiary referral centre

ECCO'20 Vienna

Year: 2020
Authors:

G. Dragoni1,2, A. Pieraccini1, S. Bagnoli1, S. Caini3, G. Macrì1, F. Rogai1, S. Milani1,2, A. Galli1,2, M. Milla1

1AOU Careggi, IBD Referral Center- Gastroenterology Unit, Firenze, Italy, 2Università Degli Studi di Firenze, Department of Experimental and Clinical Biomedical Sciences ‘Mario Serio’, Firenze, Italy, 3Institute for Cancer Research- Prevention and Clinical Network ISPRO, Molecular and Nutritional Epidemiology Unit, Firenze, Italy

P621 Physician preferences for biologics (originator vs. biosimilar) for the treatment of ulcerative colitis in France, Germany and the UK

ECCO'20 Vienna

Year: 2020
Authors:

L. Huynh1, S. Hass2, B.E. Sands3, M.S. Duh1, H. Sipsma1, M. Cheng1, A. Lax1, A. NAG4

1Analysis Group Inc., Health Economics and Outcomes Research, Boston, USA, 2H. E. Outcomes, Health Economics and Outcomes Research, Los Angeles, USA, 3Icahn School of Medicine at Mount Sinai, Dr Henry D. Janowitz Division of Gastroenterology, New York, USA, 4Shire- a Takeda company, Health Economics- Outcomes Research and Epidemiology, Lexington, USA

P622 Recovery of nutrient deficiency as a predictor of remission in inflammatory bowel diseases

ECCO'20 Vienna

Year: 2020
Authors:

A.A. Iakovlev, A. Volkov, I. Shcherbakova, G. Leonova, V. Piskovets

Rostov State Medical University, Department of Gastroenterology, Rostov-on-Don, Russian Federation